drugset / Trial / NCT05068921

A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignancy

NCT05068921

NaSingle-groupOpen-labelTreatment

Summary

A phase I clinical trial of tolerability and pharmacokinetics of TQB2858 injection in subjects with advanced malignancy.

Timeline

Start
2021-12-09
Primary completion
2023-05
Completion
2023-07

Drugs

EvaluationDrugModalityDoseRoute
Subject TQB2858 Protein / enzyme biologic 1800 mg Intravenous

Indications